|
4. Scope of consolidation
Stevanato Group S.p.A. is the parent company of the Group and it holds, directly and indirectly, interests in the Group’s main operating companies. The Group’s scope of consolidation at December 31, 2021 and 2020 is as follows:
Subsidiaries and associate
The consolidated financial statement of the Group includes the following list of company directly or indirectly controlled:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% equity interest |
Name |
|
Segment |
|
Description |
|
Country of incorporation |
|
Type of control |
|
2021 |
|
2020 |
Nuova Ompi S.r.l. |
|
Biopharmaceutical |
|
Production of drug containment systems and development of integrated solutions for the pharmaceutical industry |
|
Italy |
|
Direct |
|
100% |
|
100% |
Spami S.r.l. |
|
Engineering |
|
Production plant and machinery |
|
Italy |
|
Direct |
|
100% |
|
100% |
Stevanato Group International a.s. |
|
Holding |
|
Service/Subholding company |
|
Slovakia |
|
Direct |
|
100% |
|
100% |
Medical Glass a.s. |
|
Biopharmaceutical |
|
Production of drug containment systems |
|
Slovakia |
|
Indirect |
|
99.74% |
|
99.74% |
Stevanato Group N.A. S. de RL de CV |
|
Biopharmaceutical |
|
Service company |
|
Mexico |
|
Indirect |
|
100% |
|
100% |
Ompi N.A. S. de RL de CV |
|
Biopharmaceutical |
|
Production of drug containment systems |
|
Mexico |
|
Direct
Indirect |
|
30.76%
69.24% |
|
30.76%
69.24% |
Ompi of America inc. |
|
Biopharmaceutical |
|
Sale of drug containment systems and analytical services |
|
USA |
|
Indirect |
|
100% |
|
100% |
Ompi do Brasil I. e C. de
Em. Far. Ltda |
|
Biopharmaceutical |
|
Production of drug containment systems |
|
Brazil |
|
Direct
Indirect |
|
79%
21% |
|
79%
21% |
Ompi Pharm. Packing Techn. Co. Ltd |
|
Biopharmaceutical |
|
Production of drug containment systems |
|
China |
|
Indirect |
|
100% |
|
100% |
Innoscan A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
Indirect |
|
100% |
|
100% |
SVM Automatik A/S |
|
Engineering |
|
Production plant and machinery |
|
Denmark |
|
Indirect |
|
100% |
|
65% * |
Medirio SA |
|
Biopharmaceutical |
|
Research and development |
|
Switzerland |
|
Indirect |
|
100% |
|
100% |
Balda Medical Gmbh |
|
Biopharmaceutical |
|
Production of in-vitro diagnostic solutions |
|
Germany |
|
Direct |
|
100% |
|
100% |
Balda C. Brewer Inc. |
|
Biopharmaceutical |
|
Production of in-vitro diagnostic solutions |
|
USA |
|
Indirect |
|
100% |
|
100% |
Balda Precision Inc. |
|
Biopharmaceutical |
|
Production metal components |
|
USA |
|
Indirect |
|
100% |
|
100% |
Ompi of Japan Co., Ltd. |
|
Biopharmaceutical |
|
Sale of drug containment systems |
|
Japan |
|
Direct |
|
51% |
|
51% |
Swissfillon AG |
|
Biopharmaceutical |
|
Sterile filling services company |
|
Switzerland |
|
Associate |
|
0% |
|
26.94% |
* Not included in minority interests as there is a put and call option for full acquisition (the minority interests would have amounted to 35%).
Non-controlling interests
The non-controlling interests as at December 31, 2021 and the net profit attributable to non-controlling interests for the years ended December 31, 2020 and 2021 relate to Ompi of Japan Co., Ltd. and Medical Glass a.s.. For further details refer to Note 37.
|